SYK Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 8.48% compared to Stryker's net margin of 12.41%. Stryker's return on equity of 15.22% beat Boston Scientific's return on equity of 8.96%.

Stryker has a consensus price target of $421.86, signalling upside risk potential of 21.18%. On the other hand Boston Scientific has an analysts' consensus of $114.78 which suggests that it could grow by 20.75%. Given that Stryker has higher upside potential than Boston Scientific, analysts believe Stryker is more attractive than Boston Scientific.

Stryker has a beta of 0.929, which suggesting that the stock is 7.107% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.94%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Boston Scientific quarterly revenues of $4.6B. Stryker's net income of $546M is lower than Boston Scientific's net income of $566M. Notably, Stryker's price-to-earnings ratio is 44.86x while Boston Scientific's PE ratio is 76.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 5.94x versus 8.43x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 8.48% compared to Stryker's net margin of 28.41%. Stryker's return on equity of 15.22% beat Intuitive Surgical's return on equity of 15.6%.

Stryker has a consensus price target of $421.86, signalling upside risk potential of 21.18%. On the other hand Intuitive Surgical has an analysts' consensus of $614.67 which suggests that it could grow by 28.39%. Given that Intuitive Surgical has higher upside potential than Stryker, analysts believe Intuitive Surgical is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.107% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.94%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Intuitive Surgical quarterly revenues of $2.4B. Stryker's net income of $546M is lower than Intuitive Surgical's net income of $685.7M. Notably, Stryker's price-to-earnings ratio is 44.86x while Intuitive Surgical's PE ratio is 74.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 5.94x versus 20.75x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 8.48% compared to Stryker's net margin of 16.85%. Stryker's return on equity of 15.22% beat Insulet's return on equity of 43.11%.

Stryker has a consensus price target of $421.86, signalling upside risk potential of 21.18%. On the other hand Insulet has an analysts' consensus of $312.27 which suggests that it could grow by 27.97%. Given that Insulet has higher upside potential than Stryker, analysts believe Insulet is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.107% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.94%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than Insulet quarterly revenues of $597.5M. Stryker's net income of $546M is higher than Insulet's net income of $100.7M. Notably, Stryker's price-to-earnings ratio is 44.86x while Insulet's PE ratio is 42.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 5.94x versus 8.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 8.48% compared to Stryker's net margin of 26.88%. Stryker's return on equity of 15.22% beat ResMed's return on equity of 25.56%.

Stryker has a consensus price target of $421.86, signalling upside risk potential of 21.18%. On the other hand ResMed has an analysts' consensus of $265.42 which suggests that it could grow by 23.98%. Given that ResMed has higher upside potential than Stryker, analysts believe ResMed is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.107% less volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.94%. ResMed offers a yield of 0.97% to investors and pays a quarterly dividend of $0.53 per share. Stryker pays 40.73% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $6.4B, which are larger than ResMed quarterly revenues of $1.3B. Stryker's net income of $546M is higher than ResMed's net income of $344.6M. Notably, Stryker's price-to-earnings ratio is 44.86x while ResMed's PE ratio is 25.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 5.94x versus 6.41x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.